Cargando…
Activity of Selected Group of Monoterpenes in Alzheimer’s Disease Symptoms in Experimental Model Studies—A Non-Systematic Review
Alzheimer’s disease (AD) is the leading cause of dementia and cognitive function impairment. The multi-faced character of AD requires new drug solutions based on substances that incorporate a wide range of activities. Antioxidants, AChE/BChE inhibitors, BACE1, or anti-amyloid platelet aggregation su...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306454/ https://www.ncbi.nlm.nih.gov/pubmed/34298986 http://dx.doi.org/10.3390/ijms22147366 |
_version_ | 1783727814954975232 |
---|---|
author | Wojtunik-Kulesza, Karolina Rudkowska, Monika Kasprzak-Drozd, Kamila Oniszczuk, Anna Borowicz-Reutt, Kinga |
author_facet | Wojtunik-Kulesza, Karolina Rudkowska, Monika Kasprzak-Drozd, Kamila Oniszczuk, Anna Borowicz-Reutt, Kinga |
author_sort | Wojtunik-Kulesza, Karolina |
collection | PubMed |
description | Alzheimer’s disease (AD) is the leading cause of dementia and cognitive function impairment. The multi-faced character of AD requires new drug solutions based on substances that incorporate a wide range of activities. Antioxidants, AChE/BChE inhibitors, BACE1, or anti-amyloid platelet aggregation substances are most desirable because they improve cognition with minimal side effects. Plant secondary metabolites, used in traditional medicine and pharmacy, are promising. Among these are the monoterpenes—low-molecular compounds with anti-inflammatory, antioxidant, enzyme inhibitory, analgesic, sedative, as well as other biological properties. The presented review focuses on the pathophysiology of AD and a selected group of anti-neurodegenerative monoterpenes and monoterpenoids for which possible mechanisms of action have been explained. The main body of the article focuses on monoterpenes that have shown improved memory and learning, anxiolytic and sleep-regulating effects as determined by in vitro and in silico tests—followed by validation in in vivo models. |
format | Online Article Text |
id | pubmed-8306454 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83064542021-07-25 Activity of Selected Group of Monoterpenes in Alzheimer’s Disease Symptoms in Experimental Model Studies—A Non-Systematic Review Wojtunik-Kulesza, Karolina Rudkowska, Monika Kasprzak-Drozd, Kamila Oniszczuk, Anna Borowicz-Reutt, Kinga Int J Mol Sci Review Alzheimer’s disease (AD) is the leading cause of dementia and cognitive function impairment. The multi-faced character of AD requires new drug solutions based on substances that incorporate a wide range of activities. Antioxidants, AChE/BChE inhibitors, BACE1, or anti-amyloid platelet aggregation substances are most desirable because they improve cognition with minimal side effects. Plant secondary metabolites, used in traditional medicine and pharmacy, are promising. Among these are the monoterpenes—low-molecular compounds with anti-inflammatory, antioxidant, enzyme inhibitory, analgesic, sedative, as well as other biological properties. The presented review focuses on the pathophysiology of AD and a selected group of anti-neurodegenerative monoterpenes and monoterpenoids for which possible mechanisms of action have been explained. The main body of the article focuses on monoterpenes that have shown improved memory and learning, anxiolytic and sleep-regulating effects as determined by in vitro and in silico tests—followed by validation in in vivo models. MDPI 2021-07-08 /pmc/articles/PMC8306454/ /pubmed/34298986 http://dx.doi.org/10.3390/ijms22147366 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Wojtunik-Kulesza, Karolina Rudkowska, Monika Kasprzak-Drozd, Kamila Oniszczuk, Anna Borowicz-Reutt, Kinga Activity of Selected Group of Monoterpenes in Alzheimer’s Disease Symptoms in Experimental Model Studies—A Non-Systematic Review |
title | Activity of Selected Group of Monoterpenes in Alzheimer’s Disease Symptoms in Experimental Model Studies—A Non-Systematic Review |
title_full | Activity of Selected Group of Monoterpenes in Alzheimer’s Disease Symptoms in Experimental Model Studies—A Non-Systematic Review |
title_fullStr | Activity of Selected Group of Monoterpenes in Alzheimer’s Disease Symptoms in Experimental Model Studies—A Non-Systematic Review |
title_full_unstemmed | Activity of Selected Group of Monoterpenes in Alzheimer’s Disease Symptoms in Experimental Model Studies—A Non-Systematic Review |
title_short | Activity of Selected Group of Monoterpenes in Alzheimer’s Disease Symptoms in Experimental Model Studies—A Non-Systematic Review |
title_sort | activity of selected group of monoterpenes in alzheimer’s disease symptoms in experimental model studies—a non-systematic review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306454/ https://www.ncbi.nlm.nih.gov/pubmed/34298986 http://dx.doi.org/10.3390/ijms22147366 |
work_keys_str_mv | AT wojtunikkuleszakarolina activityofselectedgroupofmonoterpenesinalzheimersdiseasesymptomsinexperimentalmodelstudiesanonsystematicreview AT rudkowskamonika activityofselectedgroupofmonoterpenesinalzheimersdiseasesymptomsinexperimentalmodelstudiesanonsystematicreview AT kasprzakdrozdkamila activityofselectedgroupofmonoterpenesinalzheimersdiseasesymptomsinexperimentalmodelstudiesanonsystematicreview AT oniszczukanna activityofselectedgroupofmonoterpenesinalzheimersdiseasesymptomsinexperimentalmodelstudiesanonsystematicreview AT borowiczreuttkinga activityofselectedgroupofmonoterpenesinalzheimersdiseasesymptomsinexperimentalmodelstudiesanonsystematicreview |